المؤلفون: Mateos Manteca, María Victoria, Oriol, Albert, Martínez-López, Joaquín, Gutiérrez Gutiérrez, Norma Carmen, Teruel, Ana-Isabel, López de la Guía, Ana, López, Javier, Bengoechea, Enrique, Pérez, Montserrat, Polo, Marta, Palomera, Luis, De Arriba, Felipe, González, Yolanda, Hernández, José-Mariano, Granell, Miquel, Bello, José-Luis, Bargay, Joan, Peñalver, Francisco-Javier, Ribera, José-María, Martín-Mateos, María-Luisa, García Sanz, Ramón, Lahuerta, Juan José, Bladé, Joan, San Miguel Izquierdo, Jesús Fernando

مصطلحات موضوعية: Mieloma múltiple, Chromosome Aberrations, Aged, Boronic Acids, Follow-Up Studies, Humans, Pyrazines, Antineoplastic Combined Chemotherapy Protocols, Prognosis, Multiple Myeloma, Maintenance Chemotherapy, Thalidomide, In Situ Hybridization, Prednisone, Remission Induction, Survival Rate, talidomida, protocolos de quimioterapia antineoplásica combinada, humanos, inducción de remisión, anciano, estudios de seguimiento, prednisona, tasa de supervivencia, pronóstico, ácidos borónicos, hibridación in situ, quimioterapia de mantenimiento, aberraciones cromosómicas, piracinas

العلاقة: https://doi.org/10.1182/blood-2012-05-427815Test; Mateos, M. V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A. I., López de la Guía, A., . & San-Miguel, J. F. (2012). Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood, The Journal of the American Society of Hematology, 120(13), 2581-2588. https://doi.org/10.1182/blood-2012-05-427815Test. Epub 2012 Aug 13. PMID: 22889759.; http://hdl.handle.net/10366/154315Test

الإتاحة: https://doi.org/10.1182/blood-2012-05-427815Test
http://hdl.handle.net/10366/154315Test

المؤلفون: Mateos Manteca, María Victoria, Richardson, Paul G., Schlag, Rudolf, Khuageva, Nuriet K, Dimopoulos, Meletios A., Shpilberg, Ofer, Kropff, Martin, Spicka, Ivan, Petrucci, Maria T, Palumbo, Antonio, Samoilova, Olga S, Dmoszynska, Anna, Abdulkadyrov, Kudrat M, Schots, Rik, Jiang, Bin, Esseltine, Dixie-Lee, Liu, Kevin, Cakana, Andrew, van de Velde, Helgi, San Miguel Izquierdo, Jesús Fernando

مصطلحات موضوعية: Mieloma múltiple, Aged, Boronic Acids, Kaplan-Meier Estimate, Risk Assessment, Humans, Pyrazines, Melphalan, Antineoplastic Combined Chemotherapy Protocols, Recurrence, Multiple Myeloma, Time Factors, Risk Factors, Treatment Outcome, Prednisone, protocolos de quimioterapia antineoplásica combinada, humanos, factores de tiempo, anciano, factores de riesgo, prednisona, ácidos borónicos, resultado del tratamiento, recurrencia, evaluación de riesgos, piracinas, estimación de Kaplan-Meier, melfalán

العلاقة: https://doi.org/10.1200/JCO.2009.26.0638Test; Mateos, M. V., Richardson, P. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., . & San Miguel, J. F. (2010). Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. Journal of Clinical Oncology, 28(13), 2259-2266. doi:10.1200/JCO.2009.26.0638. Epub 2010 Apr 5. PMID: 20368561.; http://hdl.handle.net/10366/154346Test

الإتاحة: https://doi.org/10.1200/JCO.2009.26.0638Test
http://hdl.handle.net/10366/154346Test

المؤلفون: San Miguel Izquierdo, Jesús Fernando, Schlag, Rudolf, Khuageva, Nuriet K, Dimopoulos, Meletios A., Shpilberg, Ofer, Kropff, Martin, Spicka, Ivan, Petrucci, Maria T, Palumbo, Antonio, Samoilova, Olga S, Dmoszynska, Anna, Abdulkadyrov, Kudrat M, Schots, Rik, Jiang, Bin, Mateos Manteca, María Victoria, Anderson, Kenneth C, Esseltine, Dixie-Lee, Liu, Kevin, Cakana, Andrew, van de Velde, Helgi, Richardson, Paul G.

مصطلحات موضوعية: Mieloma múltiple, Disease Progression, Aged, Boronic Acids, Follow-Up Studies, Humans, Pyrazines, Melphalan, Antineoplastic Combined Chemotherapy Protocols, Middle Aged, Multiple Myeloma, Time Factors, Treatment Outcome, Prednisone, Survival Analysis, protocolos de quimioterapia antineoplásica combinada, humanos, factores de tiempo, anciano, estudios de seguimiento, mediana edad, prednisona, ácidos borónicos, resultado del tratamiento, análisis de supervivencia, progresión de la enfermedad, piracinas, melfalán

العلاقة: San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28;359(9):906-17. doi:10.1056/NEJMoa0801479. PMID: 18753647.; http://hdl.handle.net/10366/154297Test

الإتاحة: https://doi.org/10.1056/NEJMoa0801479Test
http://hdl.handle.net/10366/154297Test

المؤلفون: Mateos Manteca, María Victoria, Hernández, José M., Hernández, Miguel T., Gutiérrez Gutiérrez, Norma Carmen, Palomera, Luis, Fuertes, M., Díaz-Mediavilla, Joaquín, Lahuerta, Juan José, De la Rubia, Javier, Terol, María-José, Sureda, Anna, Bargay, Joan, Ribas, Paz, De Arriba, Felipe, Alegre, Adrian, Oriol, Albert, Carrera, Dolores, García-Laraña, José, García Sanz, Ramón, Bladé, Joan, Prósper, Felipe, Mateo, Gemma, Esseltine, Dixie-Lee, van de Velde, Helgi, San Miguel Izquierdo, Jesús Fernando

مصطلحات موضوعية: Mieloma múltiple, Disease-Free Survival, Immunophenotyping, Aged, Boronic Acids, Humans, Pyrazines, Melphalan, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Multiple Myeloma, Maximum Tolerated Dose, Cohort Studies, Prednisone, protocolos de quimioterapia antineoplásica combinada, humanos, anciano, supervivencia sin enfermedad, prednisona, inmunofenotipificación, ácidos borónicos, dosis máxima tolerada, estudios de cohortes, antineoplásicos, piracinas, melfalán

العلاقة: https://doi.org/10.1182/blood-2006-04-019778Test; Mateos, M. V., Hernández, J. M., Hernández, M. T., Gutiérrez, N. C., Palomera, L., Fuertes, M., . & Miguel, J. F. S. (2006). Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 108(7), 2165-2172. https://doi.org/10.1182/blood-2006-04-019778Test; http://hdl.handle.net/10366/154234Test

الإتاحة: https://doi.org/10.1182/blood-2006-04-019778Test
http://hdl.handle.net/10366/154234Test

المؤلفون: Dimopoulos, Meletios Athanasios, Gertz, Morie A, Kastritis, Efstathios, García Sanz, Ramón, Kimby, Eva K, Leblond, Veronique, Fermand, Jean-Paul, Merlini, Giampaolo, Morel, Pierre, Morra, Enrica, Ocio San Miguel, Enrique María, Owen, Roger, Ghobrial, Irene M, Seymour, John, Kyle, Robert A., Treon, Steven P

مصطلحات موضوعية: Waldenstrom Macroglobulinemia, International consensus, Treatment recommendations, International specific congress, Transplantation, Boronic Acids, Hematopoietic Stem Cell Transplantation, Antibodies, Thalidomide, Humans, Pyrazines, Drug Therapy, 3205.04 Hematología, trasplante de células madre hematopoyéticas, ácidos borónicos, talidomida, macroglobulinemia de Waldenström, humanos, trasplante, piracinas, anticuerpos, farmacoterapia

العلاقة: Dimopoulos, M. A., Gertz, M. A., Kastritis, E., Garcia-Sanz, R., Kimby, E. K., LeBlond, V., . & Treon, S. P. (2009). Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol, 27(1), 120-126. https://doi.org/10.1200/JCO.2008.17.7865Test; http://hdl.handle.net/10366/155315Test

الإتاحة: https://doi.org/10.1200/JCO.2008.17.7865Test
http://hdl.handle.net/10366/155315Test